^
    Back
    Association details:
    Biomarker:MET amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor) +
    ningetinib (CT053PTSA) (Multi-tyrosine kinase inhibitor, MERTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

    Excerpt:
    ...c-Met GCN ≥ 6 or cluster amplification is required if participant is resistant to1st or 2nd generation EGFR-TKI ;c-MET GCN statue is not required, If participant is resistant to3rd generation EGFR-TKI （osimertinib）...
    Trial ID:
    NCT03758287
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    A phase Ib study of a novel c-MET, AXL and VEGFR-2 inhibitor ningetinib and gefitinib combination therapy in Chinese EGFR-TKI resistant NSCLC with T790M negative.

    Published date:
    05/13/2020
    Excerpt:
    C-Met gene amplification by FISH was conducted in 72 pts (83.7%).Pts with higher gene copy number (GCN) responded better in treatment, ORR in the GCN ≥6 (n=11), GCN ≥5 (n=16) and GCN ≥3 (n=37) subgroups was 36.4%, 25.0% and 21.6% respectively….Ningetinib was well tolerated at 30 mg and 40 mg dosage with Gefitinib 250 mg, the RP2D for Ningetinb was 40 mg. This combination therapy showed promising anti-tumor activity in prior EGFR-TKIs acquired resistant NSCLC pts with T790M negative. C-Met GCN was the potential efficacy biomarker.
    DOI:
    10.1200/JCO.2020.38.15_suppl.9583
    Trial ID:
    NCT03758287